APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiviral Drugs for Influenza

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antiviral Drugs for Influenza Market Outlook and Growth Opportunities 2026

30 December 2025192 pages

Choose your research edition.

Industry ResearchAntiviral Drugs for Influenza Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiviral Drugs for Influenza Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Antiviral Drugs for Influenza Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiviral Drugs for Influenza Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiviral Drugs for Influenza Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Antiviral Drugs for Influenza market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antiviral Drugs for Influenza market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antiviral Drugs for Influenza market include AdvaCare Pharma, Avexima, BioCryst Pharmaceuticals, Daiichi Sankyo, Morningside Pharmaceuticals, Shionogi, Wockhardt, GlaxoSmithKline and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antiviral Drugs for Influenza market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiviral Drugs for Influenza and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiviral Drugs for Influenza sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antiviral Drugs for Influenza market size, projected growth trends, production technologies, key applications, and end-use industries.

Antiviral Drugs for Influenza Segment by Company

AdvaCare Pharma

Avexima

BioCryst Pharmaceuticals

Daiichi Sankyo

Morningside Pharmaceuticals

Shionogi

Wockhardt

GlaxoSmithKline

Roche

Teva Pharmaceuticals

Antiviral Drugs for Influenza Segment by Type

Neuraminidase Inhibitors

Polymerase Inhibitors

Antiviral Drugs for Influenza Segment by Application

Over-the-counter (OTC)

Prescription (Rx)

Antiviral Drugs for Influenza Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antiviral Drugs for Influenza status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antiviral Drugs for Influenza market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antiviral Drugs for Influenza significant trends, drivers, influence factors in global and regions.

6. To analyze Antiviral Drugs for Influenza competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for Influenza market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for Influenza and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for Influenza.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antiviral Drugs for Influenza market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiviral Drugs for Influenza industry.

Chapter 3: Detailed analysis of Antiviral Drugs for Influenza manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antiviral Drugs for Influenza in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antiviral Drugs for Influenza in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antiviral Drugs for Influenza Industry Trends Table 2. Antiviral Drugs for Influenza Industry Drivers Table 3. Antiviral Drugs for Influenza Industry Opportunities and Challenges Table 4. Antiviral Drugs for Influenza Industry Restraints Table 5. Global Antiviral Drugs for Influenza Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antiviral Drugs for Influenza Revenue Share by Company (2021-2026) Table 7. Global Antiviral Drugs for Influenza Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antiviral Drugs for Influenza Sales Volume Share by Company (2021-2026) Table 9. Global Antiviral Drugs for Influenza Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antiviral Drugs for Influenza Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antiviral Drugs for Influenza Key Company Manufacturing Base & Headquarters Table 12. Global Antiviral Drugs for Influenza Company, Product Type & Application Table 13. Global Antiviral Drugs for Influenza Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antiviral Drugs for Influenza by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Neuraminidase Inhibitors Table 18. Significant Companies of Polymerase Inhibitors Table 19. Global Antiviral Drugs for Influenza Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antiviral Drugs for Influenza Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Antiviral Drugs for Influenza Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Antiviral Drugs for Influenza Sales Volume Share by Type (2021-2026) Table 23. Global Antiviral Drugs for Influenza Sales Volume Share by Type (2027-2032) Table 24. Global Antiviral Drugs for Influenza Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antiviral Drugs for Influenza Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Antiviral Drugs for Influenza Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Antiviral Drugs for Influenza Sales Value Share by Type (2021-2026) Table 28. Global Antiviral Drugs for Influenza Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Over-the-counter (OTC) Table 30. Significant Companies of Prescription (Rx) Table 31. Global Antiviral Drugs for Influenza Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Antiviral Drugs for Influenza Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Antiviral Drugs for Influenza Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Antiviral Drugs for Influenza Sales Volume Share by Application (2021-2026) Table 35. Global Antiviral Drugs for Influenza Sales Volume Share by Application (2027-2032) Table 36. Global Antiviral Drugs for Influenza Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Antiviral Drugs for Influenza Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Antiviral Drugs for Influenza Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Antiviral Drugs for Influenza Sales Value Share by Application (2021-2026) Table 40. Global Antiviral Drugs for Influenza Sales Value Share by Application (2027-2032) Table 41. Global Antiviral Drugs for Influenza Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Antiviral Drugs for Influenza Sales by Region (2021-2026) & (K Units) Table 43. Global Antiviral Drugs for Influenza Sales Market Share by Region (2021-2026) Table 44. Global Antiviral Drugs for Influenza Sales by Region (2027-2032) & (K Units) Table 45. Global Antiviral Drugs for Influenza Sales Market Share by Region (2027-2032) Table 46. Global Antiviral Drugs for Influenza Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Antiviral Drugs for Influenza Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Antiviral Drugs for Influenza Sales Value Share by Region (2021-2026) Table 49. Global Antiviral Drugs for Influenza Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Antiviral Drugs for Influenza Sales Value Share by Region (2027-2032) Table 51. Global Antiviral Drugs for Influenza Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Antiviral Drugs for Influenza Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Antiviral Drugs for Influenza Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Antiviral Drugs for Influenza Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 56. Global Antiviral Drugs for Influenza Sales Market Share by Country (2021-2026) Table 57. Global Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 58. Global Antiviral Drugs for Influenza Sales Market Share by Country (2027-2032) Table 59. Global Antiviral Drugs for Influenza Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Antiviral Drugs for Influenza Sales Value Market Share by Country (2021-2026) Table 61. Global Antiviral Drugs for Influenza Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Antiviral Drugs for Influenza Sales Value Market Share by Country (2027-2032) Table 63. AdvaCare Pharma Company Information Table 64. AdvaCare Pharma Business Overview Table 65. AdvaCare Pharma Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio Table 67. AdvaCare Pharma Recent Development Table 68. Avexima Company Information Table 69. Avexima Business Overview Table 70. Avexima Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Avexima Antiviral Drugs for Influenza Product Portfolio Table 72. Avexima Recent Development Table 73. BioCryst Pharmaceuticals Company Information Table 74. BioCryst Pharmaceuticals Business Overview Table 75. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 77. BioCryst Pharmaceuticals Recent Development Table 78. Daiichi Sankyo Company Information Table 79. Daiichi Sankyo Business Overview Table 80. Daiichi Sankyo Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio Table 82. Daiichi Sankyo Recent Development Table 83. Morningside Pharmaceuticals Company Information Table 84. Morningside Pharmaceuticals Business Overview Table 85. Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 87. Morningside Pharmaceuticals Recent Development Table 88. Shionogi Company Information Table 89. Shionogi Business Overview Table 90. Shionogi Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Shionogi Antiviral Drugs for Influenza Product Portfolio Table 92. Shionogi Recent Development Table 93. Wockhardt Company Information Table 94. Wockhardt Business Overview Table 95. Wockhardt Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Wockhardt Antiviral Drugs for Influenza Product Portfolio Table 97. Wockhardt Recent Development Table 98. GlaxoSmithKline Company Information Table 99. GlaxoSmithKline Business Overview Table 100. GlaxoSmithKline Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio Table 102. GlaxoSmithKline Recent Development Table 103. Roche Company Information Table 104. Roche Business Overview Table 105. Roche Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Roche Antiviral Drugs for Influenza Product Portfolio Table 107. Roche Recent Development Table 108. Teva Pharmaceuticals Company Information Table 109. Teva Pharmaceuticals Business Overview Table 110. Teva Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 112. Teva Pharmaceuticals Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Antiviral Drugs for Influenza Distributors List Table 116. Antiviral Drugs for Influenza Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Antiviral Drugs for Influenza Product Image Figure 2. Global Antiviral Drugs for Influenza Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiviral Drugs for Influenza Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antiviral Drugs for Influenza Sales (2021-2032) & (K Units) Figure 5. Global Antiviral Drugs for Influenza Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antiviral Drugs for Influenza Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Neuraminidase Inhibitors Image Figure 10. Polymerase Inhibitors Image Figure 11. Global Antiviral Drugs for Influenza Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Antiviral Drugs for Influenza Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Antiviral Drugs for Influenza Sales Volume Share by Type (2021-2032) Figure 14. Global Antiviral Drugs for Influenza Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Antiviral Drugs for Influenza Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Antiviral Drugs for Influenza Sales Value Share by Type (2021-2032) Figure 17. Over-the-counter (OTC) Image Figure 18. Prescription (Rx) Image Figure 19. Global Antiviral Drugs for Influenza Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Antiviral Drugs for Influenza Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Antiviral Drugs for Influenza Sales Volume Share by Application (2021-2032) Figure 22. Global Antiviral Drugs for Influenza Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Antiviral Drugs for Influenza Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Antiviral Drugs for Influenza Sales Value Share by Application (2021-2032) Figure 25. Global Antiviral Drugs for Influenza Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Antiviral Drugs for Influenza Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Antiviral Drugs for Influenza Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Antiviral Drugs for Influenza Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Antiviral Drugs for Influenza Sales Value (2021-2032) & (US$ Million) Figure 30. North America Antiviral Drugs for Influenza Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Antiviral Drugs for Influenza Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Antiviral Drugs for Influenza Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Antiviral Drugs for Influenza Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Antiviral Drugs for Influenza Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Antiviral Drugs for Influenza Sales Value (2021-2032) & (US$ Million) Figure 36. South America Antiviral Drugs for Influenza Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Antiviral Drugs for Influenza Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Antiviral Drugs for Influenza Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Antiviral Drugs for Influenza Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Antiviral Drugs for Influenza Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Polymerase Inhibitors
Applications
  • Over-the-counter (OTC)
  • Prescription (Rx)
Companies covered
  • AdvaCare Pharma
  • Avexima
  • BioCryst Pharmaceuticals
  • Daiichi Sankyo
  • Morningside Pharmaceuticals
  • Shionogi
  • Wockhardt
  • GlaxoSmithKline
  • Roche
  • Teva Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antiviral Drugs for Influenza Sales Value (2021-2032)
  4. 1.2.2 Global Antiviral Drugs for Influenza Sales Volume (2021-2032)
  5. 1.2.3 Global Antiviral Drugs for Influenza Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antiviral Drugs for Influenza Market Dynamics
  1. 2.1 Antiviral Drugs for Influenza Industry Trends
  2. 2.2 Antiviral Drugs for Influenza Industry Drivers
  3. 2.3 Antiviral Drugs for Influenza Industry Opportunities and Challenges
  4. 2.4 Antiviral Drugs for Influenza Industry Restraints
3 Antiviral Drugs for Influenza Market by Company
  1. 3.1 Global Antiviral Drugs for Influenza Company Revenue Ranking in 2025
  2. 3.2 Global Antiviral Drugs for Influenza Revenue by Company (2021-2026)
  3. 3.3 Global Antiviral Drugs for Influenza Sales Volume by Company (2021-2026)
  4. 3.4 Global Antiviral Drugs for Influenza Average Price by Company (2021-2026)
  5. 3.5 Global Antiviral Drugs for Influenza Company Ranking (2024-2026)
  6. 3.6 Global Antiviral Drugs for Influenza Company Manufacturing Base and Headquarters
  7. 3.7 Global Antiviral Drugs for Influenza Company Product Type and Application
  8. 3.8 Global Antiviral Drugs for Influenza Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antiviral Drugs for Influenza Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antiviral Drugs for Influenza Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antiviral Drugs for Influenza Market by Type
  1. 4.1 Antiviral Drugs for Influenza Type Introduction
  2. 4.1.1 Neuraminidase Inhibitors
  3. 4.1.2 Polymerase Inhibitors
  4. 4.2 Global Antiviral Drugs for Influenza Sales Volume by Type
  5. 4.2.1 Global Antiviral Drugs for Influenza Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antiviral Drugs for Influenza Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Antiviral Drugs for Influenza Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Antiviral Drugs for Influenza Sales Value by Type
  9. 4.3.1 Global Antiviral Drugs for Influenza Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antiviral Drugs for Influenza Sales Value by Type (2021-2032)
  11. 4.3.3 Global Antiviral Drugs for Influenza Sales Value Share by Type (2021-2032)
5 Antiviral Drugs for Influenza Market by Application
  1. 5.1 Antiviral Drugs for Influenza Application Introduction
  2. 5.1.1 Over-the-counter (OTC)
  3. 5.1.2 Prescription (Rx)
  4. 5.2 Global Antiviral Drugs for Influenza Sales Volume by Application
  5. 5.2.1 Global Antiviral Drugs for Influenza Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antiviral Drugs for Influenza Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Antiviral Drugs for Influenza Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Antiviral Drugs for Influenza Sales Value by Application
  9. 5.3.1 Global Antiviral Drugs for Influenza Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antiviral Drugs for Influenza Sales Value by Application (2021-2032)
  11. 5.3.3 Global Antiviral Drugs for Influenza Sales Value Share by Application (2021-2032)
6 Antiviral Drugs for Influenza Regional Sales and Value Analysis
  1. 6.1 Global Antiviral Drugs for Influenza Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiviral Drugs for Influenza Sales by Region (2021-2032)
  3. 6.2.1 Global Antiviral Drugs for Influenza Sales by Region: 2021-2026
  4. 6.2.2 Global Antiviral Drugs for Influenza Sales by Region (2027-2032)
  5. 6.3 Global Antiviral Drugs for Influenza Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antiviral Drugs for Influenza Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antiviral Drugs for Influenza Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antiviral Drugs for Influenza Sales Value by Region (2027-2032)
  9. 6.5 Global Antiviral Drugs for Influenza Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antiviral Drugs for Influenza Sales Value (2021-2032)
  12. 6.6.2 North America Antiviral Drugs for Influenza Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antiviral Drugs for Influenza Sales Value (2021-2032)
  15. 6.7.2 Europe Antiviral Drugs for Influenza Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antiviral Drugs for Influenza Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antiviral Drugs for Influenza Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antiviral Drugs for Influenza Sales Value (2021-2032)
  21. 6.9.2 South America Antiviral Drugs for Influenza Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antiviral Drugs for Influenza Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antiviral Drugs for Influenza Sales Value Share by Country, 2025 VS 2032
7 Antiviral Drugs for Influenza Country-level Sales and Value Analysis
  1. 7.1 Global Antiviral Drugs for Influenza Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antiviral Drugs for Influenza Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antiviral Drugs for Influenza Sales by Country (2021-2032)
  4. 7.3.1 Global Antiviral Drugs for Influenza Sales by Country (2021-2026)
  5. 7.3.2 Global Antiviral Drugs for Influenza Sales by Country (2027-2032)
  6. 7.4 Global Antiviral Drugs for Influenza Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antiviral Drugs for Influenza Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antiviral Drugs for Influenza Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antiviral Drugs for Influenza Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antiviral Drugs for Influenza Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antiviral Drugs for Influenza Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AdvaCare Pharma
  2. 8.1.1 AdvaCare Pharma Company Information
  3. 8.1.2 AdvaCare Pharma Business Overview
  4. 8.1.3 AdvaCare Pharma Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio
  6. 8.1.5 AdvaCare Pharma Recent Developments
  7. 8.2 Avexima
  8. 8.2.1 Avexima Company Information
  9. 8.2.2 Avexima Business Overview
  10. 8.2.3 Avexima Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Avexima Antiviral Drugs for Influenza Product Portfolio
  12. 8.2.5 Avexima Recent Developments
  13. 8.3 BioCryst Pharmaceuticals
  14. 8.3.1 BioCryst Pharmaceuticals Company Information
  15. 8.3.2 BioCryst Pharmaceuticals Business Overview
  16. 8.3.3 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  18. 8.3.5 BioCryst Pharmaceuticals Recent Developments
  19. 8.4 Daiichi Sankyo
  20. 8.4.1 Daiichi Sankyo Company Information
  21. 8.4.2 Daiichi Sankyo Business Overview
  22. 8.4.3 Daiichi Sankyo Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio
  24. 8.4.5 Daiichi Sankyo Recent Developments
  25. 8.5 Morningside Pharmaceuticals
  26. 8.5.1 Morningside Pharmaceuticals Company Information
  27. 8.5.2 Morningside Pharmaceuticals Business Overview
  28. 8.5.3 Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  30. 8.5.5 Morningside Pharmaceuticals Recent Developments
  31. 8.6 Shionogi
  32. 8.6.1 Shionogi Company Information
  33. 8.6.2 Shionogi Business Overview
  34. 8.6.3 Shionogi Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shionogi Antiviral Drugs for Influenza Product Portfolio
  36. 8.6.5 Shionogi Recent Developments
  37. 8.7 Wockhardt
  38. 8.7.1 Wockhardt Company Information
  39. 8.7.2 Wockhardt Business Overview
  40. 8.7.3 Wockhardt Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Wockhardt Antiviral Drugs for Influenza Product Portfolio
  42. 8.7.5 Wockhardt Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Roche Antiviral Drugs for Influenza Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Teva Pharmaceuticals
  56. 8.10.1 Teva Pharmaceuticals Company Information
  57. 8.10.2 Teva Pharmaceuticals Business Overview
  58. 8.10.3 Teva Pharmaceuticals Antiviral Drugs for Influenza Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  60. 8.10.5 Teva Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antiviral Drugs for Influenza Value Chain Analysis
  2. 9.1.1 Antiviral Drugs for Influenza Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antiviral Drugs for Influenza Sales Mode & Process
  6. 9.2 Antiviral Drugs for Influenza Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antiviral Drugs for Influenza Distributors
  9. 9.2.3 Antiviral Drugs for Influenza Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst